Pinned straw:
Had a quick glance through the BOT Cannacord Genuity Preso which was released on 12 Aug 2025. It was a good summary refresher of the BOT story for me being relatively new to BOT.
What caught my eye, though, was the few slides on the "fulfilment platform" - see extracts below.
- It was interesting to see the re-positioning of the fulfilment platform as a means to improve GTN yield, expediting fulfilment etc.
- There were 18 content slides in the pack. The fulfilment platform appeared in 5 of the 18 slides, about 27% of the pack - a very decent amount of airtime, I thought.
- This positioning is almost exactly how Matt O'Callahan positioned the platform in the SM meeting - how Matt described it, and how it is positioned in this slide pack makes total sense to me - its a differentiator and will make a difference, but there is no "formal" or tangible" dependence on it to drive growth/uptake
- Quite a sharp contrast to the deafening slience on the platform in the last 2 updates, starting with "The Nightmare"
Given this airtime, this does not sound like a capability that is dead/shafted/pushed to the side ... could this be the start of the platform revival instead, I wonder?
Discl: Held IRL and in SM
@jcmleng Good points here, I think as well with the platform where they note they can take an underperforming drug and make it successful with the platform and refill model gives the possibility of an upcoming catalyst for the SP with a partnership deal or something similar for another drug.
Management also have performance incentives linked to adding another product to the platform and in the 4C webinar they said they are still doing all the relative business development stuff in the background + the hiring adds for additional sales reps mention sofdra + additional products so it would be nice if they have something in the works.
Made sense when they were only planning 25 reps, with a target of 50 reps now it is a no brainer.
Held in SM & RL